Related Experiment Video
Updated: Jul 20, 2026
Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
Published on: January 12, 2017
External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema
Cherie Lin1, Jie Su2, Alison J Wu3
1Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Importance:
Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.
Objective:
To investigate the external validity of a previously reported 5-factor model by applying it to an independent cohort of patients with breast cancer.
Design, Setting, And Participants:
This prognostic study collected data on a longitudinal cohort of patients with predominantly early-stage breast cancer treated with curative intent at the Princess Margaret Cancer Centre in Toronto, Canada between February 1, 2010, and July 31, 2014, with a median (IQR) follow-up of 4.3 (2.4-7.6) years. The 5 factors (age, body mass index, breast density, nodal burden, and use of axillary lymph node dissection [ALND]) were used as input into the established regression-based model. The analysis was performed from July 2 through August 29, 2024.
Exposure:
Lymphedema after breast cancer treatment.
Main Outcomes And Measures:
Lymphedema-free survival (LFS) was analyzed using Kaplan-Meier analysis, and sensitivity, specificity, and accuracy performance metrics of predicting breast cancer-related lymphedema were calculated.
Results:
A total of 101 female patients (median [IQR] age, 54.8 [48.8-62.3] years) were included in the analysis. These patients had localized or locoregional breast cancer treated with primary lumpectomy (90 [89%]) or mastectomy (11 [11%]); 75 (74%) had no axillary biopsy or sentinel lymph node biopsy; 26 (26%) had undergone ALND; and 38 (38%) had received chemotherapy, 101 (100%) received radiotherapy, and 64 (63%) received hormone therapy. Kaplan-Meier analysis showed a 2-year LFS of 97.5% (95% CI, 94.0%-100.0%) vs 65.0% (95% CI, 47.1%-89.7%) for the low- vs high-risk groups as defined by the 5-factor model (P < .001). The model sensitivity was 0.83 (95% CI, 0.52-0.98), specificity was 0.89 (95% CI, 0.80-0.94), and accuracy was 0.88 (95% CI, 0.80-0.94) for predicting breast cancer-related lymphedema.
Conclusions And Relevance:
These findings validate the performance of a 5-factor risk model for its prediction of 2-year LFS. Future clinical translation of this model can help with identifying patients at the highest risk of breast cancer-related lymphedema to facilitate closer surveillance and/or preventive management to improve health outcomes and quality of life.
